Literature DB >> 35750052

Genome-wide CRISPR screens of T cell exhaustion identify chromatin remodeling factors that limit T cell persistence.

Julia A Belk1, Winnie Yao2, Nghi Ly2, Katherine A Freitas3, Yan-Ting Chen4, Quanming Shi2, Alfredo M Valencia5, Eric Shifrut6, Nupura Kale7, Kathryn E Yost8, Connor V Duffy9, Bence Daniel10, Madeline A Hwee4, Zhuang Miao9, Alan Ashworth11, Crystal L Mackall12, Alexander Marson13, Julia Carnevale14, Santosh A Vardhana15, Ansuman T Satpathy16.   

Abstract

T cell exhaustion limits antitumor immunity, but the molecular determinants of this process remain poorly understood. Using a chronic stimulation assay, we performed genome-wide CRISPR-Cas9 screens to systematically discover regulators of T cell exhaustion, which identified an enrichment of epigenetic factors. In vivo CRISPR screens in murine and human tumor models demonstrated that perturbation of the INO80 and BAF chromatin remodeling complexes improved T cell persistence in tumors. In vivo Perturb-seq revealed distinct transcriptional roles of each complex and that depletion of canonical BAF complex members, including Arid1a, resulted in the maintenance of an effector program and downregulation of exhaustion-related genes in tumor-infiltrating T cells. Finally, Arid1a depletion limited the acquisition of exhaustion-associated chromatin accessibility and led to improved antitumor immunity. In summary, we provide an atlas of the genetic regulators of T cell exhaustion and demonstrate that modulation of epigenetic state can improve T cell responses in cancer immunotherapy.
Copyright © 2022 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CRISPR; T cell exhaustion; canonical BAF complex; chromatin remodeling; epigenetics; genomics; immunology; in vivo Perturb-seq

Mesh:

Substances:

Year:  2022        PMID: 35750052     DOI: 10.1016/j.ccell.2022.06.001

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   38.585


  4 in total

Review 1.  Targeting the alterations of ARID1A in pancreatic cancer: tumorigenesis, prediction of treatment, and prognostic value.

Authors:  Ruichao Li; Guangbing Xiong; Jun Zhao; Lin Yang
Journal:  Am J Transl Res       Date:  2022-09-15       Impact factor: 3.940

Review 2.  Clinical implications of T cell exhaustion for cancer immunotherapy.

Authors:  Andrew Chow; Karlo Perica; Christopher A Klebanoff; Jedd D Wolchok
Journal:  Nat Rev Clin Oncol       Date:  2022-10-10       Impact factor: 65.011

3.  Experimental verification and validation of immune biomarkers based on chromatin regulators in ischemic stroke.

Authors:  Beibei Yu; Yunze Tian; Yongfeng Zhang; Boqiang Lv; Jianzhong Li; Shouping Gong
Journal:  Front Genet       Date:  2022-08-29       Impact factor: 4.772

4.  ARID1A deficiency reverses the response to anti-PD(L)1 therapy in EGFR-mutant lung adenocarcinoma by enhancing autophagy-inhibited type I interferon production.

Authors:  Dantong Sun; Haili Qian; Jinsong Wang; Tongji Xie; Fei Teng; Junling Li; Puyuan Xing
Journal:  Cell Commun Signal       Date:  2022-10-13       Impact factor: 7.525

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.